Results 31 to 40 of about 871,767 (407)
Technology in Cancer Research & Treatment, 2020 Background: The efficacy of next-generation epidermal growth factor receptor-tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer who have failed first-generation epidermal growth factor receptor-tyrosine kinase inhibitors ...
Yi-Tian Qi MM +2 more
doaj +1 more source
Nature Communications, 2020 Diarrhoea is one of the most burdensome and common adverse events of chemotherapeutics, and has no standardised therapy to date. Increasing evidence suggests that the gut microbiome can influence the development of chemotherapy-induced diarrhoea. Here we
G. Ianiro +17 more
semanticscholar +1 more source
Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma
Therapeutic Advances in Medical Oncology, 2020 The treatment landscape of metastatic renal cell carcinoma (mRCC) has been transformed with the advent of antiangiogenics, notably tyrosine kinase inhibitors (TKIs) targeting vascular endothelial growth factor receptor (VEGFR), and immune checkpoint ...
E. Rassy, R. Flippot, L. Albiges
semanticscholar +1 more source
EGF regulates tyrosine phosphorylation and membrane-translocation of the scaffold protein Tks5 [PDF]
, 2013 Background: Tks5/FISH is a scaffold protein comprising of five SH3 domains and one PX domain. Tks5 is a substrate of the tyrosine kinase Src and is required for the organization of podosomes/invadopodia implicated in invasion of tumor cells.
Buday, László +5 more
core +1 more source
Proteinuria and hypertension with tyrosine kinase inhibitors [PDF]
Kidney International, 2011 Tyrosine kinases are important for the development of pathological angiogenesis, a critical factor for survival and proliferation of tumor cells. Inhibition of tyrosine kinases either through targeted binding of its ligands or inhibition of its receptor has led to significant hindrance in angiogenesis and has improved survival for several cancers ...
Rajiv Agarwal +2 more
openaire +3 more sources
Identification of tyrosine kinase inhibitors that halt Plasmodium falciparum parasitemia.
PLoS ONE, 2020 Although current malaria therapies inhibit pathways encoded in the parasite's genome, we have looked for anti-malaria drugs that can target an erythrocyte component because development of drug resistance might be suppressed if the parasite cannot mutate ...
Kristina Kesely +7 more
doaj +1 more source
Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors : Current Status and Future Directions [PDF]
, 2015 Imatinib is strongly positioned as the recommended first-line agent for most patients with advanced gastrointestinal stromal tumor (GIST) due to its good efficacy and tolerability.
Bauer, Sebastian, Joensuu, Heikki
core +1 more source
Kinase profiling of liposarcomas using RNAi and drug screening assays identified druggable targets. [PDF]
, 2017 BackgroundLiposarcoma, the most common soft tissue tumor, is understudied cancer, and limited progress has been made in the treatment of metastatic disease.
Doan, Ngan B +9 more
core +2 more sources
Targeting Btk/Etk of prostate cancer cells by a novel dual inhibitor. [PDF]
, 2014 Btk and Etk/BMX are Tec-family non-receptor tyrosine kinases. Btk has previously been reported to be expressed primarily in B cells and has an important role in immune responses and B-cell malignancies.
Bhardwaj, G +16 more
core +2 more sources
Tyrosine Kinase Inhibitors as Antiangiogenic Drugs in Multiple Myeloma
Pharmaceuticals, 2010 Tyrosine kinase inhibitors are a new class of anticancer drugs, that are capable of directly interacting with the catalytic site of the target enzyme and thereby inhibiting catalysis. Therapeutically useful tyrosine kinase inhibitors are not specific for
Domenico Ribatti
doaj +1 more source